{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T04:56:59Z","timestamp":1766725019509,"version":"3.48.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Research on HDV prevalence among people with HBV\/HIV coinfection in China is limited. The impact of HDV on antiretroviral therapy (ART) efficacy and liver disease progression in this population remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included people with HBV\/HIV-1 between 2005 and 2022. Baseline plasma was tested for HDV IgM\/IgG; HDV RNA was measured if antibodies were positive. Demographics, liver complications, and ART responses were compared by HDV status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 1130 people with HBV\/HIV-1 were included, of whom 84 (7.4%) tested positive for HDV antibodies. Among these, 19 (22.6%) were HDV RNA-positive. Approximately 41.7% of HDV antibody-positive individuals had HCV coinfection. The median duration of ART was 7.4 years (interquartile range [IQR]: 5.1, 9.9). Longitudinal samples were available from 14 individuals with HDV RNA positivity. Baseline HDV RNA was 2.98 (IQR: 2.17, 4.78) log10\u2005IU\/mL. After a rapid decline during ART, 92.8% (13\/14) of individuals reached undetectable levels at 7 years. When adjusted for HCV infection, HIV and HBV virological suppression, HBsAg clearance, and immunological nonresponders were comparable between HDV antibody-positive and -negative individuals (all P &amp;gt; .05), and between HDV RNA-positive and -negative individuals (all P &amp;gt; .05). The incidence rates of newly developed cirrhosis and hepatocellular carcinoma were also similar.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HDV coinfection was observed in 7.4% of people with HBV\/HIV-1, as a defective virus reliant on HBV, HDV RNA declined rapidly during long-term ART and HDV coinfection did not compromise HIV or HBV treatment efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofaf764","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T13:15:17Z","timestamp":1765372517000},"source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of Hepatitis D and Its Impact on the Clinical Efficacy of Antiretroviral Therapy in People With HBV\/HIV-1 in Guangdong Province, China"],"prefix":"10.1093","volume":"13","author":[{"given":"Yaozu","family":"He","sequence":"first","affiliation":[{"name":"Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University , Guangzhou ,","place":["China"]},{"name":"Guangzhou Medical Research Institute of Infectious Diseases , Guangzhou ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyin","family":"Lin","sequence":"additional","affiliation":[{"name":"Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University , Guangzhou ,","place":["China"]},{"name":"Guangzhou Medical Research Institute of Infectious Diseases , Guangzhou ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[{"name":"Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University , Guangzhou ,","place":["China"]},{"name":"Guangzhou Medical Research Institute of Infectious Diseases , Guangzhou ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Gu","sequence":"additional","affiliation":[{"name":"Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University , Guangzhou ,","place":["China"]},{"name":"Guangzhou Medical Research Institute of Infectious Diseases , Guangzhou ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianglong","family":"Lan","sequence":"additional","affiliation":[{"name":"Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University , Guangzhou ,","place":["China"]},{"name":"Guangzhou Medical Research Institute of Infectious Diseases , Guangzhou ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinhua","family":"Liu","sequence":"additional","affiliation":[{"name":"Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University , Guangzhou ,","place":["China"]},{"name":"Guangzhou Medical Research Institute of Infectious Diseases , Guangzhou ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeyang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University , Guangzhou ,","place":["China"]},{"name":"Guangzhou Medical Research Institute of Infectious Diseases , Guangzhou ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RongHong","family":"Li","sequence":"additional","affiliation":[{"name":"Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University , Guangzhou ,","place":["China"]},{"name":"Guangzhou Medical Research Institute of Infectious Diseases , Guangzhou ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruiying","family":"He","sequence":"additional","affiliation":[{"name":"Institute of Infectious Disease, Guangzhou Eighth People's Hospital, Guangzhou Medical University , Guangzhou ,","place":["China"]},{"name":"Guangzhou Key Laboratory of Clinical Pathogen Research for Infectious Diseases Guangzhou ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiping","family":"Cai","sequence":"additional","affiliation":[{"name":"Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University , Guangzhou ,","place":["China"]},{"name":"Guangzhou Medical Research Institute of Infectious Diseases , Guangzhou ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Tang","sequence":"additional","affiliation":[{"name":"Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University , Guangzhou ,","place":["China"]},{"name":"Institute of Infectious Disease, Guangzhou Eighth People's Hospital, Guangzhou Medical University , Guangzhou ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5711-8681","authenticated-orcid":false,"given":"Linghua","family":"Li","sequence":"additional","affiliation":[{"name":"Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University , Guangzhou ,","place":["China"]},{"name":"Guangzhou Medical Research Institute of Infectious Diseases , Guangzhou ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"2025122523314618200_ofaf764-B1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(10)61931-9","article-title":"Hepatitis delta virus","volume":"378","author":"Hughes","year":"2011","journal-title":"Lancet"},{"key":"2025122523314618200_ofaf764-B2","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/jvh.13577","article-title":"Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: a systematic review and meta-analysis of longitudinal studies","volume":"28","author":"Kamal","year":"2021","journal-title":"J Viral Hepat"},{"key":"2025122523314618200_ofaf764-B3","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jhep.2010.06.008","article-title":"Outcome of chronic delta hepatitis in Italy: a long-term cohort study","volume":"53","author":"Niro","year":"2010","journal-title":"J Hepatol"},{"key":"2025122523314618200_ofaf764-B4","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jhep.2023.10.043","article-title":"Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories","volume":"80","author":"Polaris Observatory Collaborators","year":"2024","journal-title":"J Hepatol"},{"key":"2025122523314618200_ofaf764-B5","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/infdis\/jiz633","article-title":"Estimating the global prevalence, disease progression, and clinical outcome of hepatitis Delta virus infection","volume":"221","author":"Miao","year":"2020","journal-title":"J Infect Dis"},{"key":"2025122523314618200_ofaf764-B6","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J Hepatol"},{"key":"2025122523314618200_ofaf764-B7","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/gutjnl-2018-316601","article-title":"Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis","volume":"68","author":"Chen","year":"2019","journal-title":"Gut"},{"key":"2025122523314618200_ofaf764-B8","doi-asserted-by":"crossref","first-page":"e37016","DOI":"10.2196\/37016","article-title":"Underestimated prevalence of HIV, hepatitis B virus (HBV), and hepatitis D virus (HDV) triple infection globally: systematic review and meta-analysis","volume":"8","author":"Chen","year":"2022","journal-title":"JMIR Public Health Surveill"},{"key":"2025122523314618200_ofaf764-B9","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/QAD.0000000000001424","article-title":"Hepatitis delta and HIV infection","volume":"31","author":"Soriano","year":"2017","journal-title":"AIDS"},{"key":"2025122523314618200_ofaf764-B10","doi-asserted-by":"crossref","first-page":"1086012","DOI":"10.3389\/fmed.2023.1086012","article-title":"Prevalence of HDV infection in people living with HIV: data from a multicenter Italian cohort","volume":"10","author":"Nicolini","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2025122523314618200_ofaf764-B11","volume-title":"Guidelines for the prevention, diagnosis, care and treatment of persons with chronic hepatitis B infection","author":"World Health Organization","year":"2024"},{"key":"2025122523314618200_ofaf764-B12","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1097\/CM9.0000000000002886","article-title":"Incidence and factors associated with hepatitis B surface antigen seroclearance in patients co-infected with HBV\/HIV during antiretroviral therapy in guangdong, China","volume":"136","author":"He","year":"2023","journal-title":"Chin Med J (Engl)"},{"key":"2025122523314618200_ofaf764-B13","doi-asserted-by":"crossref","first-page":"e70114","DOI":"10.1002\/jmv.70114","article-title":"Hepatic flare following effective antiretroviral therapy is associated with HBsAg seroclearance in HBV\/HIV-1 co-infection","volume":"96","author":"Lin","year":"2024","journal-title":"J Med Virol"},{"key":"2025122523314618200_ofaf764-B14","first-page":"629","article-title":"AIDS professional group society of infectious diseases Chinese medical association: guidelines for diagnosis and treatment of HIV\/AIDS in China (2011)","volume":"29","year":"2011","journal-title":"ZHONGHUA CHUAN RAN BING ZA ZHI"},{"key":"2025122523314618200_ofaf764-B15","first-page":"3","article-title":"Consensus on diagnosis and management of immunological non-responder in acquired immunodeficiency syndrome (version 2023)","volume":"42","author":"Chinese Society of Infectious Diseases, AIDS and Hepatitis C Professional Group","year":"2024","journal-title":"Chin J Infect Dis"},{"key":"2025122523314618200_ofaf764-B16","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijid.2023.12.014","article-title":"The prevalence of HDV among HBsAg-positive populations with and without HIV-1 in China","volume":"140","author":"Wang","year":"2024","journal-title":"Int J Infect Dis"},{"key":"2025122523314618200_ofaf764-B17","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae655","article-title":"Incidence and outcome of hepatitis D virus infection in people with HIV in the era of tenofovir-containing antiretroviral therapy","author":"Huang","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2025122523314618200_ofaf764-B18","first-page":"485","article-title":"Epidemiology and challenges of HBV\/HIV co-infection amongst HIV-infected patients in endemic areas: review","volume":"13","author":"Weldemhret","year":"2021","journal-title":"HIV AIDS (Auckl)"},{"key":"2025122523314618200_ofaf764-B19","doi-asserted-by":"crossref","first-page":"e640","DOI":"10.1016\/S2352-3018(23)00151-0","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial","volume":"10","author":"Avihingsanon","year":"2023","journal-title":"Lancet HIV"},{"key":"2025122523314618200_ofaf764-B20","doi-asserted-by":"crossref","first-page":"e70081","DOI":"10.1002\/jmv.70081","article-title":"Profiles of lymphocyte subtypes in HIV-infected people with different immunologic responses to antiretroviral therapy","volume":"96","author":"Zhao","year":"2024","journal-title":"J Med Virol"},{"key":"2025122523314618200_ofaf764-B21","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/liv.15804","article-title":"Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: data from the ICONA cohort","volume":"44","author":"d'Arminio Monforte","year":"2024","journal-title":"Liver Int"},{"key":"2025122523314618200_ofaf764-B22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jhep.2016.10.007","article-title":"Hepatitis delta-associated mortality in HBV\/HIV-coinfected patients","volume":"66","author":"\u00e9guelin","year":"2017","journal-title":"J Hepatol"},{"key":"2025122523314618200_ofaf764-B23","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jhep.2019.12.028","article-title":"Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1","volume":"72","author":"Spaan","year":"2020","journal-title":"J Hepatol"},{"key":"2025122523314618200_ofaf764-B24","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jhep.2020.06.038","article-title":"Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta","volume":"73","author":"Roulot","year":"2020","journal-title":"J Hepatol"},{"key":"2025122523314618200_ofaf764-B25","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1111\/liv.16006","article-title":"Long-term outcome of hepatitis delta in different regions world-wide: results of the hepatitis Delta international network","volume":"44","author":"Wranke","year":"2024","journal-title":"Liver Int"},{"key":"2025122523314618200_ofaf764-B26","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/cid\/cix125","article-title":"Impact of tenofovir on hepatitis Delta virus replication in the Swiss human immunodeficiency virus cohort study","volume":"64","author":"B\u00e9guelin","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2025122523314618200_ofaf764-B27","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1097\/QAD.0000000000000417","article-title":"Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients","volume":"28","author":"Soriano","year":"2014","journal-title":"AIDS"},{"key":"2025122523314618200_ofaf764-B28","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/j.jhep.2016.02.013","article-title":"The hepatitis delta virus: replication and pathogenesis","volume":"64","author":"Sureau","year":"2016","journal-title":"J Hepatol"},{"key":"2025122523314618200_ofaf764-B29","doi-asserted-by":"crossref","first-page":"6630","DOI":"10.1128\/jvi.65.12.6630-6636.1991","article-title":"Small-form hepatitis B surface antigen is sufficient to help in the assembly of hepatitis delta virus-like particles","volume":"65","author":"Wang","year":"1991","journal-title":"J Virol"},{"key":"2025122523314618200_ofaf764-B30","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1128\/JVI.79.10.6570-6573.2005","article-title":"Failure of the lamivudine-resistant rtM204I hepatitis B virus mutants to efficiently support hepatitis delta virus secretion","volume":"79","author":"Vietheer","year":"2005","journal-title":"J Virol"},{"key":"2025122523314618200_ofaf764-B31","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1099\/0022-1317-79-5-1115","article-title":"Interaction between hepatitis delta virus-encoded proteins and hepatitis B virus envelope protein domains","volume":"79","author":"Hourioux","year":"1998","journal-title":"J Gen Virol"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/1\/ofaf764\/66127959\/ofaf764.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/1\/ofaf764\/66127959\/ofaf764.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T04:31:58Z","timestamp":1766723518000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf764\/8404848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf764","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,12,26]]},"article-number":"ofaf764"}}